Catalyst Biosciences, Inc. (CBIO)

$1.79

+0.01 (+0.56%)
Rating:
Recommendation:
Neutral
Symbol CBIO
Price $1.79
Beta 1.897
Volume Avg. 6.52M
Market Cap 56.344M
Shares () -
52 Week Range 0.35-5.2
1y Target Est -
DCF Unlevered CBIO DCF ->
DCF Levered CBIO LDCF ->
ROE -149.54% Strong Sell
ROA -198.72% Strong Sell
Operating Margin -
Debt / Equity 48.70% Neutral
P/E -
P/B 2.08 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest CBIO news


Dr. Nassim Usman
Healthcare
Biotechnology
NASDAQ Capital Market

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD); and CB 4332 for patients with deficiencies in complement factor I (CFI), including dAMD. The company also develops ProTUNE C3b/C4b degrader and ImmunoTUNE C3a/C5a degrader platforms designed to target other disorders of the complement or inflammatory pathways. It has a strategic research collaboration with Mosaic Biosciences, Inc.; and license and collaboration agreement with Biogen International GmbH. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.